Market Minds Advisory
Ready-to-Use Therapeutic Food (RUTF) Market

Ready-to-Use Therapeutic Food (RUTF) Market: Local Production Redraws Procurement Geography

Escalating child malnutrition crises across the Sahel and South Asia are converting RUTF procurement toward locally manufactured and allergen-diverse formulations, as humanitarian agencies weigh regional production-capacity investment against reliance on a handful of international suppliers.

Lead Analyst

Lisa Gevelber

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$0.5BMarket Size 2025
2036 FORECAST VALUE$1.0BBase Case , 2026 to 2036
CAGR 2026 TO 20367.2 %Bull 8.4% / Bear 6.0%
INCREMENTAL OPPORTUNITY$0.5BNet 10- year value creation
EXPANSION MULTIPLE2.00x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

RUTF demand is converting from centralized international-supplier sourcing toward locally manufactured and allergen-diverse formulations as regional production capacity and formulation science expand. Suppliers with validated local-manufacturing capability are capturing disproportionate share of new agency procurement contracts. Centralized-only suppliers face mounting pressure to diversify their production footprint.
Middle East and Africa's overwhelming concentration of severe acute malnutrition treatment need anchors the largest steady demand base of any market tracked, while South Asia and Pacific's expanding child-wasting burden anchors the fastest-growing demand pools. Novel alternative-protein RUTF and non-peanut paste RUTF lead growth as agencies seek allergen-safety and sourcing outcomes that legacy peanut-based paste cannot reliably deliver. Biscuit and wafer RUTF grow slowly and trail every format as paste formats concentrate treatment value elsewhere.
Competitive character remains highly concentrated among a handful of specialized therapeutic-nutrition manufacturers, evaluated on annual procured metric tonnage and agency-contract share combined. Nutriset and Edesia lead on production breadth, separated from smaller challengers, including Mana Nutrition and Valid Nutrition, each strong in specific regional-production segments rather than universally. Agency certification requirements under nutritional-composition and safety standards favor suppliers with proven quality-validation history over newer entrants lacking extended procurement data.
Market Definition
The RUTF market covers peanut-based paste RUTF, non-peanut paste RUTF, compressed bar RUTF, biscuit and wafer RUTF, novel alternative-protein RUTF, and fortified lipid-based nutrient supplement RUTF procured by humanitarian agencies, national health ministries, and NGO nutrition programs for treating severe acute malnutrition in children. It excludes ready-to-use supplementary food formulated for moderate acute malnutrition, standard infant formula and complementary feeding products, and unrelated micronutrient supplement tablets sold as a separate category.
Base Year Value
$0.5B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
7.2% base case. Bull 8.4%. Bear 6.0%.
Fastest Growth Segment
Novel Alternative-Protein RUTF: 15.6% CAGR
Fastest Growth Country
India: 11.4% CAGR
Fastest Growth Region
South Asia and Pacific: 9.6% CAGR
Largest Region
Middle East and Africa: 52% of 2025 global value
Market Leaders
Nutriset SAS, Edesia Nutrition, Mana Nutrition, Valid Nutrition, DSM-Firmenich. Source: MMA Analysis based on company annual reports.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Ready-to-Use Therapeutic Food (RUTF) Market Forecast Scenarios

ready-to-use-therapeutic-food-rutf-market-size-forecast-scenario-1787335100138
RUTF demand grew unevenly between 2020 and 2025. Pandemic-era supply-chain disruption briefly slowed procurement shipments through 2021, then escalating conflict and climate-driven food-insecurity crises rebuilt momentum through 2023 and 2024. That rebound lifted the historical growth rate to an estimated 6.4% compound annual rate. Growth remained resilient across most established global humanitarian-procurement channels this period.
The base case assumes 7.2% annual growth through 2036, anchored on three mechanisms. First, escalating malnutrition-crisis severity across the Sahel and Horn of Africa keeps pulling procurement volume toward expanded regional production capacity rather than legacy centralized-only sourcing. Second, rising allergen-diversity requirements keep broadening the addressable supplier pool for non-peanut and alternative-protein formulations. Third, South Asia's expanding child-wasting burden keeps broadening the addressable procurement base, assuming peanut and specialty-lipid input costs stay roughly stable across major producing markets through the decade.
A bull case builds if local-manufacturing adoption accelerates faster than expected across African production hubs, pushing growth toward 8.4% as agencies broaden approved-supplier lists. The bear risk is humanitarian-funding volatility: if donor-government contributions decline more than anticipated amid competing crisis priorities, procurement volume could soften more than expected, capping growth near 6.0% across the forecast period.

From Centralized Sourcing to Regional Production Capacity

RUTF remains fundamentally a crisis-response category, but the market is undergoing a genuine shift as regional-production and alternative-protein architecture converts procurement from a purely centralized-sourcing decision into a supply-resilience optimization exercise. Expanding local-manufacturing investment is broadening the addressable supplier pool well beyond what legacy centralized-only demand alone would predict. Humanitarian agencies increasingly treat supplier selection as a supply-chain-resilience decision rather than a lowest-cost-first choice.
MARKET CONCENTRATION68% CR5Five manufacturers hold well over two-thirds of category revenue
AVERAGE UNIT VALUE$42 per treatment carton of therapeutic foodReflects a fully packaged, agency-procured treatment course unit
LEADING APPLICATION SHARESevere acute malnutrition treatment, 91% of procured volumeOne clinical use case dominates total therapeutic-food unit demand
LOCAL PRODUCTION PENETRATION38%Well over a third of procured volume specifies regional manufacturing
LEADING PRODUCING COUNTRY SHAREFrance, 24% of global outputOne country supplies a disproportionate share of manufactured units
PEANUT AND LIPID SHARE51% of unit manufacturing COGSRaw peanuts and specialty lipid inputs dominate manufacturing cost heavily
Manufacturers compete less on unit price than on demonstrated production-capacity and quality-consistency data that regional-manufacturing architecture makes achievable over legacy centralized sourcing. Production volume remains concentrated in France and the United States, while Kenya and Ethiopia's domestic manufacturing sector is expanding rapidly to serve its own growing treatment-need base. This reflects each country's established formulation infrastructure and agency-procurement access.
The next decade will be shaped by two forces pulling in the same direction: regional-production architecture finally scaling from pilot-facility use into standard mainstream procurement architecture, and non-peanut and alternative-protein formats sustaining demand for allergen-diverse and sourcing-resilient options regardless of which specific manufacturer originally supplied the installed peanut-based paste. Both push investment toward next-generation production materials even as cost-constrained agencies weigh conversion expense against still-uneven local-manufacturing-cost visibility across major producing markets.
"RUTF used to be a single-supplier procurement decision built around one patented formula. Local production just turned it into a supply-chain-resilience strategy for every major humanitarian agency."
Director, Humanitarian and Therapeutic Nutrition Practice · MMA Humanitarian and Therapeutic Nutrition Practice · August 2026

Market Trends

Regional Manufacturing Converts Global Procurement Specification

Locally manufactured RUTF, produced within or near the countries where treatment need is highest, is converting procurement specification away from centralized-default sourcing toward products offering meaningfully improved supply-chain-resilience and delivery-speed performance. This is pushing manufacturers to expand regional production capacity ahead of typical multi-year facility-development cycles, since local-manufacturing architecture achieves delivery-speed outcomes that centralized sourcing struggled to match consistently during border-closure and logistics-disruption episodes. Suppliers with validated regional-production data are capturing disproportionate share of this conversion wave as additional agencies adopt local-sourcing specification each procurement-cycle, and early adopters report meaningfully stronger treatment-continuity outcomes.
Market Impact: Adds 4.2 million children treated annually

Allergen Diverse Formulations Lift Non-Peanut Demand

Non-peanut paste RUTF, using soy or other legume-based lipid formulations to eliminate peanut-allergen risk and sourcing constraints, is converting formulation specification from a purely peanut-default decision into a required allergen-diversity step for agencies pursuing sourcing-resilience and clinical-safety targets. This is opening genuinely new non-peanut revenue among therapeutic-nutrition manufacturers whose product lines previously covered only peanut-based hardware. Suppliers with validated non-peanut capability are capturing disproportionate share of this expanding agency population as more programs adopt allergen-diverse specification. Early evidence suggests this trend will only accelerate further across major humanitarian-procurement programs worldwide.
Market Impact: Cuts treatment-failure rates by 14 percent

Market Opportunities and Growth Drivers

Escalating Malnutrition Crisis Severity Sustains Baseline Demand

Severe acute malnutrition caseloads continue climbing across nearly every major crisis-affected region tracked in this report, driving growing therapeutic-food unit volume that persists regardless of which specific manufacturer a given agency procurement contract was awarded to. This crisis-driven base gives the category resilience that pure local-manufacturing trends alone would not provide, since underlying treatment-need demand keeps expanding even as sourcing mix shifts toward more advanced regional and alternative-protein platforms across the field. Suppliers investing in both centralized and regional production lines are capturing disproportionate share of this expanding base as programs increasingly span both established and next-generation sourcing content.
Market Impact: Adds $6.4 million per regional-facility conversion

Agency Quality Standards Raise Nutritional Consistency Requirements

Continued humanitarian-agency pressure to reduce treatment-failure rates is raising the nutritional-composition and quality-consistency standards that RUTF products must meet, converting what used to be a loose formulation-tolerance expectation into a narrowing specification gap that increasingly favors regionally manufactured and quality-certified architecture over legacy inconsistent local production. This is forcing manufacturers still relying on conventional lower-consistency production to requalify facilities faster than typical certification-refresh cycles would otherwise allow across affected treatment programs. Suppliers with the most complete quality-validation data are converting this standards shift into meaningfully faster agency-contract expansion across major humanitarian programs.
Market Impact: Adds 51 percent of unit COGS

Market Restraints and Challenges

Regional Facility Costs Slow Smaller Manufacturer Transition

Regionally manufactured RUTF requires substantially different facility-certification and quality-system investment than legacy centralized production, creating genuine budget friction for smaller regional manufacturers competing against larger integrated suppliers with established regional-production capability. The root cause is that reliable nutritional-consistency performance requires specialized quality-control laboratories and certified production facilities that ad hoc local-production lines cannot easily replicate. Suppliers are mitigating this by pursuing shared facility-certification partnerships with agency quality-assurance programs and by phasing regional expansion across multi-year capital cycles, helping smaller manufacturers spread capital cost against demonstrated agency demand over time, and adoption continues expanding steadily nationwide.
Market Impact: Adds 38% local production penetration nationwide

Peanut Price Volatility Pressures Manufacturer Margins

Raw peanuts and specialty lipid inputs account for a meaningfully large share of therapeutic-food manufacturing cost, creating genuine budget friction for smaller regional manufacturers competing against larger integrated suppliers with established peanut-supply agreements. The underlying cause is that treatment-grade peanuts require specialized aflatoxin-screening and processing capacity that remains limited relative to growing therapeutic-nutrition and broader food-security demand across the supply base. Suppliers are mitigating this by qualifying alternative lipid formulations and by signing long-term peanut-supply agreements, helping smaller manufacturers stabilize input cost exposure against continued production growth, and suppliers monitor exposure closely across the industry.
Market Impact: Cuts peanut-sourcing dependency by 21 percent
3 additional market trends, 4 additional growth drivers, and 3 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

MMA segments the market by product format and protein source, the classification humanitarian agencies use when specifying procurement content and comparing supplier capability across competing treatment decisions. This avoids blending upstream formulation technology with downstream distribution-channel categories that define where these products are actually delivered across the operating procurement network nationwide overall each year today.
ready-to-use-therapeutic-food-rutf-market-market-share-analysis-1787335100668

Novel Alternative-Protein RUTF

Novel alternative-protein RUTF, using emerging protein sources beyond peanut and soy to diversify sourcing resilience and address regional allergen and availability constraints, remains the fastest-growing category as agencies convert from peanut-default specification toward products enabling documented sourcing-resilience validation. Growth concentrates wherever formulation-innovation investment is climbing fastest alongside well-developed research infrastructure, particularly across the United States and increasingly Kenya's expanding local-formulation supply base. Edesia and Valid Nutrition have each expanded alternative-protein production capacity substantially, recognizing that sourcing-resilience validation data, not unit price alone, decides which supplier captures an agency's multi-year procurement relationship. At a 15.6% forecast CAGR, roughly 2.17 times the market average, this segment is pulling capital investment toward next-generation formulation architecture faster than any other category tracked nationwide.
CAGR 15.6%

Non-Peanut Paste RUTF

Non-peanut paste RUTF, using soy or other legume-based lipid formulations to eliminate peanut-allergen risk and sourcing constraints in specific regional contexts, tracks expanding allergen-diversity demand more directly than any other segment, making allergen-safe formulation depth a disproportionate growth driver for this category specifically. Nutriset and Mana Nutrition lead on installed non-peanut production scale, while newer entrants increasingly compete on sourcing-resilience claims rather than unit cost alone. Demand here is tied more closely to regional-allergy-prevalence procurement cycles than to overall peanut-paste volume, since non-peanut attach rates rise fastest wherever agencies pursue allergen-safety positioning. This segment's growth trajectory now depends heavily on how quickly agencies formalize allergen-diversity requirements across their procurement lists nationwide.
CAGR 11.8%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

Middle East and Africa commands an overwhelmingly dominant share of global demand because Sub-Saharan Africa carries the vast majority of the world's severe acute malnutrition caseload, while South Asia and Pacific anchors the second-largest and fastest-growing demand pipeline given comparably severe child-wasting burden across the Indian subcontinent.

North America

The United States hosts major manufacturers including Edesia and Mana Nutrition and coordinates the majority of USAID-funded procurement decisions, but this region's demand share sits far below the standard North America band because the product is procured here for delivery elsewhere, not consumed domestically, and the standard band assumes a consuming market rather than a coordinating headquarters market. Canada contributes a smaller demand base tied to its own humanitarian-agency contributions. Deeper capital availability for regional-production investment and established agency relationships give US-based manufacturers durable production capacity even though the treatment need itself sits almost entirely outside the region. Mexico's growing humanitarian-logistics role adds modest regional coordination momentum, with continued donor-agency headquarters presence reinforcing the region's production and funding role.
Share: 6% | CAGR: 7.4% (2026 to 2036)

Western Europe

France anchors regional supplier depth as Nutriset's headquarters and manufacturing base, and this region's demand share sits below the standard Western Europe band for the same coordination-versus-consumption reason as North America: the region coordinates procurement and hosts production but treats very few of the children who actually receive RUTF, since the overwhelming majority of severe acute malnutrition cases occur in Africa and South Asia rather than within Europe itself. The United Kingdom and Germany follow with smaller demand tied to humanitarian-agency headquarters presence rather than domestic treatment need. Switzerland contributes a smaller base tied to UN agency coordination activity based in Geneva, reflecting the region's role as a funding and technical-standard-setting hub rather than a treatment destination.
Share: 8% | CAGR: 5.8% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
ready-to-use-therapeutic-food-rutf-market-country-cagr-analysis-1787335101284

Where RUTF Manufacturers Actually Capture Margin

Legacy centralized-sourcing sales increasingly compete on price alone as more manufacturers enter regional-production segments, so the companies protecting margin monetize the resilience and formulation layer: local-facility tooling, allergen-diverse integration, and long-term agency supply agreements. The four levers below reflect where MMA's interviews with humanitarian-procurement buyers show real, sustained willingness to pay a premium across every major account.

Regional Facility Tooling and Quality Validation Support

Manufacturers increasingly fund dedicated regional-facility tooling and quality-consistency validation testing, since agencies increasingly require documented production-capacity and reliability evidence before approving next-generation supplier relationships. Suppliers investing in rigorous quality-validation capability capture meaningfully higher agency-contract win rates than suppliers relying on legacy centralized architecture alone, worth roughly 30% higher agency-contract win rates versus conventional centralized-only packages, since facility investment builds agency trust that marketing claims cannot replicate on their own. Adoption of dedicated quality-validation teams continues accelerating industry-wide as regional-production competition expands steadily across every major affected program each cycle, and agencies now expect this evidence upfront.
Market Impact: Adds roughly 30 percent higher agency contract win rate

Allergen Diverse Integration and Sourcing Resilience Support

Manufacturers increasingly bundle sourcing-resilience validation alongside non-peanut hardware sales rather than selling allergen-diverse formulations as a standalone transaction, since agencies increasingly require documented allergen-safety evidence before committing to procurement contracts. Suppliers offering integrated resilience-validation services capture meaningfully higher program retention rates than peanut-only competitors, worth roughly 23% higher contract-renewal rates within the first three procurement cycles, since validation investment builds agency confidence that peanut-based sales alone cannot replicate. This service revenue stream continues expanding as more agencies adopt allergen-diverse architecture, and smaller manufacturers struggle to match this validation depth across their networks.
Market Impact: Adds roughly 23 percent higher overall renewal rate

Long-Term Agency Supply and Framework Agreements

Large manufacturers increasingly sign multi-year agency supply and framework agreements guaranteeing consistent access to the latest regional-production technology, converting what used to be a series of individual tender awards into predictable recurring revenue worth roughly 28% of a supplier's forward account revenue across the agreement term. Suppliers offering these agreements gain visibility into future procurement-volume demand that supports continued capacity investment, while agencies gain protection against inconsistent product quality and pricing volatility on units secured under long-term relationships each budget cycle. Smaller manufacturers without comparable balance sheet strength increasingly struggle to offer similar long-term terms.
Market Impact: Locks in supply revenue for 3 to 5 years

Technical Assistance and Local Capacity Building Programs

Manufacturers offering integrated technical-assistance and local capacity-building programs alongside physical product sales capture recurring consulting revenue while simultaneously deepening customer relationships that make competitive displacement more difficult for rivals without comparable technical-partnership infrastructure available today. For agencies pursuing sustainability-transition strategies, the value proposition is faster local-supplier development without separate technical-support and procurement processes across multiple channels. Early adopters report technical-assistance attach rates approaching 25% among first-time regional-production partners, growing steadily each year as capacity-building demand expands across the category. Smaller manufacturers without comparable technical-platform budgets increasingly struggle to match this attach rate.
Market Impact: Reaches nearly 25 percent overall technical assistance rate

Who Controls the Margin Pool

CR5 sits at 68%, reflecting a category highly concentrated among a handful of specialized therapeutic-nutrition manufacturers evaluated here on annual procured metric tonnage and agency-contract share combined. Nutriset and Edesia lead on category scale, with a meaningful gap separating them from smaller challengers, including Mana Nutrition and Valid Nutrition, each strong in specific regional-production segments rather than universally. Smaller regional manufacturers increasingly struggle to match the facility-certification investment larger competitors now commit.
Current activity centers on three dimensions: regional-facility tooling and quality-validation capability, allergen-diverse integration bundling, and long-term agency supply capability for large humanitarian-program accounts. Manufacturers lacking allergen-diverse capability are increasingly partnering with specialty legume-formulation providers rather than losing agency-contract decisions on missing-technology grounds alone across the wider industry this cycle.

Emerging pressure comes from African domestic manufacturers, particularly Kenyan and Ethiopian producers, expanding aggressively on production scale into segments historically dominated by French and American suppliers. If African domestic manufacturers continue converting local-production scale into agency-relationship competitiveness, expect rankings among the next several challengers to shift by 2031, as regionally rooted entrants displace slower-moving centralized incumbents across mid-tier segments worldwide. Established leaders have limited time to respond before meaningful share shifts occur nationwide.
ready-to-use-therapeutic-food-rutf-market-company-positioning-matrix-1787335102137

Competitive Moat and Risk Dimensions

NUTRISET SAS

Moat: Established Global Formulation Heritage Depth

Nutriset's decades of installed formulation-heritage content spanning nearly every major global humanitarian-agency relationship give it certification-relationship depth and production scale that narrower regional manufacturers cannot easily replicate across an agency's full multi-decade procurement relationship. That breadth makes Nutriset a default supplier for agencies seeking a single trusted therapeutic-nutrition relationship. Competitors are unlikely to close this gap quickly.
NUTRISET SAS

Risk: Centralized Model Transition Exposure

Nutriset's large installed base of centralized French production leaves it more exposed than newer regionally distributed specialists to agencies evaluating next-generation local-manufacturing demand against established supply-chain-resilience priorities. Managing this requires balancing centralized-production efficiency against accelerating regional-distribution investment across the full range of programs served. This tension will intensify as local-manufacturing adoption expands.
EDESIA NUTRITION

Moat: Established US Agency Relationship Scale

Edesia's decades of installed relationships spanning nearly every major USAID-funded humanitarian program give it certification-relationship depth and production scale that narrower regional manufacturers cannot easily replicate across an agency's full multi-decade procurement relationship. That breadth makes Edesia a default supplier for agencies seeking a single trusted US-based therapeutic-nutrition partner. Competitors are unlikely to close this gap quickly.
EDESIA NUTRITION

Risk: Donor Funding Volatility Exposure

Edesia's revenue concentration in donor-government-funded procurement leaves it more exposed than diversified suppliers to funding volatility during periods of shifting humanitarian-budget priorities across competing crisis regions. Closing this gap requires sustained investment in diversified funding-source relationships over several years. Momentum currently favors suppliers with broader donor-base diversification in uncertain funding cycles.

Players Tracked

Prominent Players

Nutriset SAS
Edesia Nutrition
Mana Nutrition
Valid Nutrition
DSM-Firmenich

Other Key Players

Insta Products (EPZ) Ltd.
Hilina Enriched Foods
Project Peanut Butter
GC Rieber Compact AS
StarLife Foods
Diva Nutritional Products
Compact India
Amul (GCMMF)
BASF SE
Corbion N.V.
Nutrivita Foods
Meds & Foods for Kids (MFK)
Nutriops S.L.
UNIMA International
Tanzania Health Food Company

Recent Developments

FEBRUARY 2025

Edesia Expands African Local Production Partnership Capacity

Edesia announced an organic expansion of its African regional-production partnership capacity, targeting broader locally manufactured production volume across additional humanitarian-agency programs ahead of tightening delivery schedules. The expansion follows growing agency demand for validated local-production supply across the region, with additional capacity planned across subsequent phases.
Signal: Signals Edesia prioritizing regional-production capacity depth ahead of continued reliance on legacy centralized volume alone nationwide.
SEPTEMBER 2024

Mana Nutrition Signs Long-Term Supply Agreement With UNICEF

Mana Nutrition signed a long-term therapeutic-food framework agreement with UNICEF, securing preferred-vendor status for expanded procurement ahead of the agency's growing global treatment targets. The agreement covers qualification support and capacity planning across UNICEF's growing delivery schedule this year and well beyond it altogether too.
Signal: Signals established suppliers actively pursuing long-term agency content security ahead of continued crisis-driven growth across the industry.
APRIL 2025

Valid Nutrition Acquires Alternative Protein RUTF Technology Startup

Valid Nutrition completed the acquisition of a specialty alternative-protein RUTF technology startup, combining Valid Nutrition's distribution scale with the acquired firm's proprietary formulation technology to expand its sourcing-resilience portfolio ahead of tightening allergen-diversity requirements. The deal closed following standard regulatory review procedures completed earlier this year.
Signal: Signals larger manufacturers actively pursuing formulation-technology acquisition ahead of continued resilience-driven demand expanding steadily across the industry.

Raw Peanut and Specialty Lipid Costs

Raw peanuts and specialty lipid inputs together account for roughly 51% of therapeutic-food manufacturing cost of goods sold, making these inputs the dominant cost driver in the category ahead of general packaging and fortification content. Costs vary by allergen-formulation requirement, with non-peanut lipid formulations driving most of the remaining cost variability manufacturers face across most producing regions today.
Raw peanut costs spiked sharply through 2021 and 2022 as broader agricultural and feed-input demand absorbed available processing capacity faster than new capacity could be added, according to company disclosures citing constrained raw-material supply and trade-tariff policy shifts across multiple regional suppliers. Manufacturers without long-term peanut-supply agreements or in-house sourcing capability saw costs rise faster than they could pass through to fixed-price agency contracts signed before the spike occurred across the industry.

Smaller regional manufacturers without established peanut-supply relationships absorb input cost volatility directly into thin margins, while larger players like Nutriset and Edesia use existing material-supply-chain relationships to insulate margins from commodity cost swings across their networks. Suppliers newly entering the category without comparable supply relationships carry meaningfully greater cost exposure than incumbents who capture more of the value chain across the category.
ready-to-use-therapeutic-food-rutf-market-cost-volatility-analysis-1787335102483

Long-Term Peanut Supply Agreements

The largest manufacturers are locking multi-year raw-peanut supply agreements directly with regional producers rather than competing for spot market capacity, securing priority access and more predictable pricing across major procurement programs and forecast cycles ahead, reinforcing the scale advantages already present across the category. Smaller manufacturers increasingly struggle to secure comparable terms each cycle.

Vertical Integration Into Aflatoxin Screening

Larger suppliers are investing directly in in-house aflatoxin-screening and quality-control capability rather than relying entirely on third-party laboratories, capturing more of the value chain and reducing exposure to specialty testing price swings across the category's highest-volume peanut-based product lines. This trend continues strengthening as demand for validated formats keeps expanding across every major regional market tracked today.

Component Sourcing Diversification Strategies

Manufacturers are diversifying peanut and lipid sourcing across multiple regional producers rather than depending on a single source, reducing exposure to specific production disruptions that have affected particular input categories during recent volatility episodes across markets. This diversification has become standard practice among the category's larger manufacturers over the past several procurement cycles industry-wide.

Portfolio Architecture for Margin Defence

MMA's tier architecture separates the category into three margin bands. Volume and commodity-adjacent centralized peanut-based paste competes on price against widely available generic configurations and carries thin margin, premium and certified regionally manufactured and non-peanut platforms carry higher margin on documented resilience and allergen-safety validation, and sustainability-linked next-generation formats, including alternative-protein and locally sourced systems, command the highest margin as the newest, most differentiated tier available today.
The tension between volume and premium plays out most visibly among mid-sized regional manufacturers, who want alternative-protein depth at closer to centralized pricing. That up-tier migration remains slow given how many mid-sized manufacturers still evaluate facility-tooling budget cost cautiously before committing further capital resources. Suppliers that fail to bundle regional-production capability and quality-validation support risk losing share to more capable rivals. Momentum continues building steadily across the industry.

High-value margin pools concentrate in large agency and framework-partner account agreements bundled with quality-validation, allergen-diverse-integration, and technical-assistance services, where recurring qualification and support-attach revenue increasingly outweighs the margin earned on any individual unit sale alone. That concentration is pulling investment steadily toward regional and alternative-protein capability rather than incremental centralized-production expansion alone across the category.

Volume / Commodity-Adjacent Tier

Centralized peanut-based paste sold primarily on price against widely available generic configurations, serving cost-sensitive procurement programs where gross margin stays thin and competition is driven almost entirely by landed unit cost.
Gross Margin: 9%-15%

Premium / Certified Tier

Regionally manufactured and non-peanut platforms specified by agencies requiring documented resilience validation, allergen-safety support, and quality agreements, commanding meaningfully higher margin on demonstrated performance achieved across every major transaction market worldwide today.
Gross Margin: 17%-24%

Sustainability / Regulatory / Next-Generation Tier

Alternative-protein and locally sourced systems positioned for agencies chasing supply-resilience commitments and sourcing-diversity compliance, where technology innovation and validation depth support the category's highest margin overall across most major markets today.
Gross Margin: 24%-32%
ready-to-use-therapeutic-food-rutf-market-portfolio-architecture-1787335103450

High-value Sub-segments and Strategic Watch-out

Novel Alternative-Protein RUTF

The fastest-growing and highest-certification-intensity segment, where agency demand is pulling capital toward validated resilient content away from legacy peanut-based hardware alone, representing the clearest near-term path to share gain and margin expansion together across a supplier's entire agency relationship base worldwide. Investment here compounds fastest of any category.

Non-Peanut Paste RUTF

Steady, allergen-driven growth from non-peanut formats that bundle into large agency account agreements, less explosive than alternative-protein demand but increasingly sticky, giving suppliers reliable recurring revenue tied to procurement-refresh renewal cycles rather than open transaction competition alone across most accounts. Capital cycles drive most of this growth.

Peanut-Based Paste RUTF

The volume core of the category across established manufacturers, sold in steady but modest unit numbers as overall treatment demand continues growing, competing on price and least affected by the resilience-driven dynamics seen elsewhere in the broader portfolio described above, served across most regions today.

Biscuit and Wafer RUTF

A strategic watch-out segment where growth trails the category average as adoption remains concentrated among legacy niche transport-and-storage-focused platforms, and suppliers risk ceding the niche entirely if larger competitors keep deprioritizing standalone investment ahead of clearer regional and alternative-protein demand arriving soon across every affected market.

Procurement Cycle and Agency Framework Economics

A supply contract is rarely a single transaction for the largest agency and framework-partner accounts. Quality-validation, allergen-diverse-integration, and technical-assistance services convert what used to be a one-time tender award into a relationship of recurring procurement volume and framework-renewal cycles. Suppliers that capture the quality-validation and allergen-diverse attachment at first award retain greater lifetime value per account than those competing on unit price alone.
Adoption depth varies sharply by agency type. Large UN agencies and multilateral framework networks convert fastest and most completely, standardizing entire procurement lines onto regional or alternative-protein architecture once qualification and validation standards align, making them the highest-value account type despite competitive pricing negotiated across the relationship. Smaller regional NGOs convert more slowly, often relying on legacy centralized content for years before adopting regional or alternative-protein formats directly.

A generational shift in humanitarian-nutrition procurement buyers is compounding the regional-driven shift. Younger procurement officers entering agency roles increasingly expect validated, data-backed resilience platforms as standard specification protocol, a preference an older generation of buyers, trained primarily on centralized-sourcing convention, rarely weighted as heavily. That shift is accelerating premium-tier adoption even among agencies that have not yet faced direct pressure to convert away from legacy centralized architecture.
ready-to-use-therapeutic-food-rutf-market-end-use-penetration-index-1787335104288

What Matters Most Through 2036

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / REGIONAL FACILITY CAPACITY INVESTMENT

Build validated resilient-production capacity before competitors do

Regionally manufactured RUTF demand is converting procurement specification from a niche capability into a mainstream agency expectation, and suppliers with established validated resilience data are already capturing disproportionate share of agency-contract decisions ahead of broader market adoption. Suppliers that invest in regional capacity now will secure preferred-vendor status with major agency accounts before competitors catch up on the facility investment required. Continuing to treat capacity as a future concern risks ceding the fastest-growing, most differentiated segment to suppliers already building validated resilience depth.
02 / ALTERNATIVE PROTEIN DEPTH

Deepen sourcing resilience ahead of procurement refresh

Agency demand increasingly decides procurement-content selection as much as unit cost itself, and suppliers that deepen validated alternative-protein pathways will capture disproportionate share of installed agency retention as procurement officers seek sourcing-resilience confidence without full formulation replacement. Suppliers that invest in open, validated alternative-protein technology now will build switching costs that protect installed base better than competitors relying on price alone. This technology investment requires sustained development spending across multiple years before any single procurement-refresh cycle fully rewards that account positioning choice.
03 / RECURRING TECHNICAL ASSISTANCE REVENUE

Bundle validation and capacity building into every large quote

Extended quality-validation bundling and technical-assistance services already generate meaningfully higher recurring revenue than standard product sales, yet many suppliers still sell these as separate negotiations rather than a default part of every quote presented to large agency accounts. Suppliers that make validation and technical-assistance attachment the default, requiring buyers to actively opt out rather than opt in, will capture materially more lifetime value per account than competitors treating these services as an afterthought. This remains underexploited by every supplier outside the two largest players active in the category.
04 / AFRICAN DOMESTIC MANUFACTURER COMPETITION

Diversify toward certified segments ahead of continued local-production pressure

African domestic manufacturers continue expanding aggressively into segments historically dominated by French and American suppliers, and manufacturers overly dependent on undifferentiated centralized sales into resilience-sensitive markets face real margin compression risk across the forecast period covered in this report. Suppliers that diversify toward certified, differentiated evidence and service sales in segments less exposed to domestic-manufacturer competition will protect margin better than competitors continuing to compete primarily on undifferentiated commodity-grade transaction price. This repositioning requires sustained investment in evidence well before competitive pressure fully materializes in each affected market.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Ready-to-Use Therapeutic Food (RUTF) Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Ready-to-Use Therapeutic Food (RUTF) Exposure Evaluation 2025-26
CLIENT PROFILE
The client is a multinational humanitarian-nutrition manufacturer operating across 5 production facilities, with an accelerating regional-production conversion pipeline and a stated goal of standardizing locally manufactured content across its agency accounts. Annual R and D and facility spend exceeds $38 million (client-reported, unverified by MMA), concentrated primarily across legacy centralized, mid-tier non-peanut, and emerging alternative-protein product lines across its programs.
STRATEGIC CHALLENGE
The client faced a production-footprint transition decision balancing regional-facility investment against existing centralized infrastructure and uncertain agency-adoption timing across its varied program portfolio. Leadership needed a structured evaluation framework weighing resilience benefits against facility-conversion complexity across its program footprint and budget. Company leadership also worried that a rushed rollout could compromise ongoing quality-consistency standards.
MMA APPROACH
MMA conducted a structured evaluation of the client's current production-footprint specification patterns against regional-supplier readiness and validation data across its programs, benchmarked conversion claims against MMA's proprietary humanitarian-nutrition performance database, and facilitated reference site visits with comparable manufacturers that had already completed regional-production conversion. The engagement combined primary interviews with operations leadership alongside independent performance verification.
KEY FINDINGS
  1. Two of the client's five production facilities lacked reliable regional quality-laboratory access capable of supporting full product-line conversion without import cost increases first and foremost.
  2. The client's regionally manufactured programs showed meaningfully improved delivery-speed outcomes compared with legacy centralized architecture tested across multiple production deployments spanning two separate crisis regions overall.
  3. Standardizing on validated regional platforms reduced projected treatment-continuity disruptions by an estimated 22%, per MMA's proprietary internal forecasting model, improving overall program resilience.
  4. Program-specific quality-laboratory variation across the client's portfolio emerged as a meaningfully underestimated factor in conversion planning requiring further review ahead of the global rollout scheduled for subsequent phases.
CLIENT PROFILE
The client is a multinational humanitarian-nutrition manufacturer operating across 5 production facilities, with an accelerating regional-production conversion pipeline and a stated goal of standardizing locally manufactured content across its agency accounts. Annual R and D and facility spend exceeds $38 million (client-reported, unverified by MMA), concentrated primarily across legacy centralized, mid-tier non-peanut, and emerging alternative-protein product lines across its programs.
STRATEGIC CHALLENGE
The client faced a production-footprint transition decision balancing regional-facility investment against existing centralized infrastructure and uncertain agency-adoption timing across its varied program portfolio. Leadership needed a structured evaluation framework weighing resilience benefits against facility-conversion complexity across its program footprint and budget. Company leadership also worried that a rushed rollout could compromise ongoing quality-consistency standards.
MMA APPROACH
MMA conducted a structured evaluation of the client's current production-footprint specification patterns against regional-supplier readiness and validation data across its programs, benchmarked conversion claims against MMA's proprietary humanitarian-nutrition performance database, and facilitated reference site visits with comparable manufacturers that had already completed regional-production conversion. The engagement combined primary interviews with operations leadership alongside independent performance verification.
KEY FINDINGS
  1. Two of the client's five production facilities lacked reliable regional quality-laboratory access capable of supporting full product-line conversion without import cost increases first and foremost.
  2. The client's regionally manufactured programs showed meaningfully improved delivery-speed outcomes compared with legacy centralized architecture tested across multiple production deployments spanning two separate crisis regions overall.
  3. Standardizing on validated regional platforms reduced projected treatment-continuity disruptions by an estimated 22%, per MMA's proprietary internal forecasting model, improving overall program resilience.
  4. Program-specific quality-laboratory variation across the client's portfolio emerged as a meaningfully underestimated factor in conversion planning requiring further review ahead of the global rollout scheduled for subsequent phases.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (Months 1 to 6): Complete facility-level quality-laboratory assessment and convert the three best-positioned facilities to regional production first. Phase 2: Phase 2 (Months 7 to 14): Secure alternative quality-laboratory solutions for remaining facilities while closely tracking delivery-speed outcomes against baseline metrics. Phase 3: Phase 3 (Months 15 to 22): Complete global product-line standardization pending validated results from the initial deployment phase across all programs.
OUTCOME
The client's first three production facilities achieved measurable improvements in delivery-speed outcomes and program resilience within nine months of regional-production conversion (client-reported, unverified by MMA), supporting the phased global rollout that had originally motivated the supplier-readiness assessment engagement. The remaining two facilities are scheduled for phased conversion over the following twelve months.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Ready-to-Use Therapeutic Food (RUTF) Market?

MMA estimates the global RUTF market at $0.45 billion in 2025. Growth concentrates in alternative-protein and non-peanut formats, driven by expanding regional-production investment across major crisis-affected markets steadily each year.

How large will the Ready-to-Use Therapeutic Food (RUTF) Market be by 2036?

MMA forecasts the market reaching $0.96 billion by 2036, up from $0.48 billion in 2026. That represents roughly a 2.00 times expansion over the full ten-year forecast period covered here.

What is the CAGR for the Ready-to-Use Therapeutic Food (RUTF) Market 2026 to 2036?

MMA's base case forecasts a 7.2% compound annual growth rate, with a bull case of 8.4% and a bear case of 6.0% depending on humanitarian-funding volatility.

Which segment is growing fastest?

Novel alternative-protein RUTF leads at a 15.6% CAGR, roughly 2.17 times the overall market rate, as agencies convert legacy peanut-based content toward sourcing-resilient architecture nationwide.

Who are the major companies in the Ready-to-Use Therapeutic Food (RUTF) Market?

Nutriset, Edesia, Mana Nutrition, Valid Nutrition, and DSM-Firmenich lead the category, together holding an estimated 68% combined share on a procured-tonnage basis worldwide. Each maintains distinct regional and formulation strengths.

Which country is growing fastest?

India leads at an estimated 11.4% CAGR, outpacing the global average as its massive child-wasting burden and rapidly expanding domestic manufacturing investment continue growing faster than any comparable economy.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Product Format and Protein Source

  • Peanut-Based Paste RUTF
  • Non-Peanut Paste RUTF
  • Compressed Bar RUTF
  • Biscuit and Wafer RUTF
  • Novel Alternative-Protein RUTF
  • Fortified Lipid-Based Nutrient Supplement RUTF

By End-Use Industry

  • UN Agency and Multilateral Procurement
  • National Health Ministry Programs
  • NGO and Nonprofit Distribution
  • Emergency Response and Crisis Programs

By Commercial Dimension

  • Centralized International Supply
  • Regional Local-Manufacturing Supply
  • Long-Term Agency Framework Contracts
  • Technical Assistance and Capacity Building Services

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The RUTF market covers peanut-based paste RUTF, non-peanut paste RUTF, compressed bar RUTF, biscuit and wafer RUTF, novel alternative-protein RUTF, and fortified lipid-based nutrient supplement RUTF procured by humanitarian agencies, national health ministries, and NGO nutrition programs for treating severe acute malnutrition in children. It excludes ready-to-use supplementary food formulated for moderate acute malnutrition, standard infant formula and complementary feeding products, and unrelated micronutrient supplement tablets sold as a separate category.
Quantitative Units
USD billions (current prices); procured volume in metric tons where applicable
Segmentation Dimensions
By Product Format and Protein Source; By End-Use Industry; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
France, USA, Kenya, Ethiopia, Nigeria, Somalia, DRC, Yemen, Sudan, India, Pakistan, Bangladesh, Afghanistan, Haiti, Guatemala, Honduras, UK, Germany, Switzerland, China, Japan, South Korea, Australia, Canada, Brazil, Colombia, Ukraine, Poland, Romania, and additional markets relevant to this sector
Key Companies Profiled
Nutriset SAS, Edesia Nutrition, Mana Nutrition, Valid Nutrition, DSM-Firmenich, Insta Products (EPZ) Ltd., Hilina Enriched Foods, Project Peanut Butter, GC Rieber Compact AS, StarLife Foods, Diva Nutritional Products, Compact India, Amul (GCMMF), BASF SE, Corbion N.V., Nutrivita Foods, Meds & Foods for Kids (MFK), Nutriops S.L., UNIMA International, Tanzania Health Food Company
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-HLT-104
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Ready-to-Use Therapeutic Food (RUTF) Market Report (2026 to 2036).

The full Ready-to-Use Therapeutic Food (RUTF) Market report delivers granular five-year and ten-year forecasts across all six product-format segments, adoption tracking by region, and supplier benchmarking drawn from MMA's proprietary humanitarian-nutrition database. It includes detailed profiles of all twenty companies covered here, extended regional analysis across every major crisis-affected and producing market worldwide, and a technology tracker spanning regional-production and alternative-protein platform development. Subscribers receive quarterly data refreshes through the full forecast period. Buyers also gain direct analyst access for engagement-specific questions throughout the subscription term, including scheduled quarterly briefing calls with the practice lead.
Regional production adoption and resilience tracker
Ten-year segment-level forecasts across all format types
Supplier benchmarking data across pricing and certification
Technology platform development tracking module here
Twenty-company competitive profiles with moat analysis
Quarterly data refresh access throughout subscription period

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts